Pfizer’s arthritis drug Xeljanz shows lifesaving benefits in hospitalized COVID-19 patients U.S. injects $3B-plus into COVID-19 research to develop antiviral pill within a year GSK, Bayer stand by CureVac following 'disappointing' COVID-19 vaccine trial flop CureVac's first-gen COVID-19 vaccine misses the mark with 47% efficacy, as share price halves in after-hours trading Mayo Clinic, nference AI analysis finds no real-world link among COVID-19 vaccines and brain blood clots Warp Speed initiative sent COVID-19 vaccine clinical trials into hyperdrive, new research shows New COVID-19 approach exploits protein response in human cells to combat virus Danaher strikes $9.6B buyout for next-gen contract manufacturing player Aldevron Researchers develop fast COVID-19 test using atom-thick sheets of graphene Healthcare industry groups cheer Supreme Court decision to uphold ACA COVID-19 tracker: U.S. to spend $3.2B on antiviral pill discovery; EU won't set 50% efficacy bar for vaccines Featured Story | By Angus Liu Pfizer's BioNTech-partnered COVID-19 vaccine Comirnaty may be getting all the attention these days, but the pharma giant’s anti-inflammatory drug Xeljanz just chalked up a win in treating patients hospitalized with the disease. read more |
| |
|---|
|
| | Who’s Watching Your Clinical Trial Supply Chain? With the ever-increasing costs of clinical trials and the advantages of being first-to-market, it’s time to take a closer look at your supply chain to ensure it delivers with speed, efficiency, and quality — all within your budget. Learn about key strategies for mitigating risk in clinical trials. Learn more. |
Top Stories By Kyle LaHucik The U.S. government has given nearly $20 billion to COVID-19 vaccines. Now, the focus shifts to oral antiviral pills to help prevent serious illness and hospitalizations of COVID-19 and other potential pandemic viruses. read more By Noah Higgins-Dunn Two drugmakers working with Germany's CureVac on pandemic shots said they're standing behind the company—for now—after disappointing late-stage results showed its vaccine was just 47% effective against COVID-19. read more By Kyle LaHucik,Noah Higgins-Dunn German biopharmaceutical CureVac said its first-generation COVID-19 vaccine, CVnCoV, showed less than 50% efficacy against any severity of the disease. read more By Andrea Park The study’s results were published not long after the FDA paused and unpaused the use of J&J's vaccine, amid reports of at least eight cases of rare brain blood clots, including one woman who died from the condition. read more By Kyle LaHucik When the U.S. formed Operation Warp Speed toward the beginning of the COVID-19 pandemic last spring, drug developers, clinical research organizations and other players felt the weight behind the initiative’s urgent name. The pandemic forced CROs like IQVIA to rethink and boost resources, because the “clear traditional timelines would not be sufficient” to get COVID-19 vaccines to the public quickly, the company said in a new report. read more By Angus Liu The development of COVID-19 drugs has mostly focused on directly targeting the SARS-CoV-2 coronavirus. But scientists at the University of Cambridge are taking a different approach to treating the disease by looking at an infection response pathway in human cells. read more By Eric Sagonowsky Looking to make a big splash in the next-gen pharma manufacturing market, Danaher has laid out $9.6 billion to buy leading contract manufacturer Aldevron, a key player the supply chain for vaccines and gene and cell therapries. read more By Conor Hale Researchers at the University of Illinois Chicago have potentially found a new method of passively detecting the coronavirus using sheets of graphene, one of the thinnest and strongest materials on the planet. read more By Paige Minemyer The long-awaited decision was cheered by healthcare groups, which had warned for months that striking down the law would cause ripple effects across the industry in an unprecedented way. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner The U.S. said it will spend more than $3 billion to discover to discover an antiviral pill that could thwart COVID-19 early in an infection. The EU's drug regulator won't impose a 50% efficacy threshold for pandemic shots, potentially good news for CureVac's vaccine. And more headlines. read more |
